. Although there was no significant correlation between serum adiponectin levels and AHI or %T<90, serum adiponectin levels were chosen at a determinant factor of %T<90.
Introduction

Obstructive sleep apnea syndrome (OSAS) is defined as repeated episodes of upper airway occlusion during sleep. Approximately 4% of middle-aged men and 2% of middleaged women are estimated to have OSAS (1). Although the main symptom of OSAS is daytime hypersomnolence, OSAS patients are often complicated with type 2 diabetes mellitus, hypertension and other diseases involving metabolic syndrome
. It is well known that OSAS and these metabolic syndrome diseases are strongly related to obesity; however, a recent study has suggested that OSAS is associated with atherosclerotic risk factors independent of obesity (4, 5) . (8) .
Recently, adipocytokines, adipocyte-specific secreted proteins, were considered to be involved in the progression of these atherosclerotic diseases. Of all adipokines, leptin and adiponectin have received the most attention. Leptin, a product of the ob gene, is a single-chain proteohormone that is thought to play a key role in the regulation of body weight. Despite the anti-obesity effects of leptin, obese individuals often have increased serum leptin levels, and leptin administration to obese individuals shows only very limited effects on obesity (6, 7). A recent study has suggested that the lack of effectiveness of leptin in treating obesity is the result of T a b l e 1 . P a t i e n t Ch a r a c t e r i s t i c s desensitization to leptin signals, and this condition is referred to as leptin resistance
In contrast, it is well known that serum levels of adiponectin are decreased in obese individuals (9) . Adiponectin is an adipocyte-specific, secreted protein that plays a role in glucose and lipid homeostasis, in addition to antiatherogenic and anti-diabetic effects. In a clinical study, a negative correlation between obesity and serum adiponectin was established, and decreased adiponectin levels in obese individuals as well as increased adiponectin levels concomitant with weight loss have been shown (10, 11) . Furthermore, reduced serum adiponectin levels are associated with insulin resistance and hyperinsulinemia, and many investigations have shown a relationship between adiponectin and type 2 diabetes mellitus (12) .
In OSAS patients, previous studies have shown a relationship between OSAS and serum leptin (13) (14) (15) or adiponectin levels (16) (17) (18) Informed consent was given by all subjects.
Material and Methods
Subjects
Sleep study
All-night polysomnography was recorded in all subjects using a computerized system (PSG E-series TM 
, Compumedics
T a b l e 2 . L e v e l s o f L e p t i n a n d Ad i p o n e c t i n 
of fasting blood sugar (FBS), serum insulin, total cholesterol, triglycerides (TG), high-density lipoprotein (HDL)-cholesterol and low-density lipoprotein (LDL)-cholesterol were measured in the morning after polysomnograph (PSG) recording by the hospital laboratory according to routine procedures. The insulin resistance index was then calculated by homeostasis model assessment (HOMA-IR) using fasting blood glucose and insulin concentrations (21).
Measurement of adiponectin and leptin by ELISA
Results
Patient characteristics
The clinical characteristics of this study group are shown in Table 1 
T a b l e 3 . Co r r e l a t i o n s b e t we e n L e p t i n a n d E a c h Va r i a b l e
Serum adiponectin level in OSAS patients
There were no significant differences in the serum levels of adiponectin among the three groups ( (22, 23) . (22, 23) . In the present study, we showed a significant and strong correlation between BMI and serum leptin levels in OSAS patients. Co r r e l a t i o n s b e t we e n Ad i p o n e c t i n a n d E a c h Va r i a b l (24) and Ip et al (5) , in which the degree of obesity was a more important determinant of leptin levels in OSAS patients than the severity of OSAS. In contrast to serum leptin levels, serum adiponectin levels are known to be decreased in obese patients, and weight loss increases serum adiponectin levels (6) . Since serum adiponectin is well reflected by the degree of obesity, many studies have examined the relationships between adiponectin and metabolic syndrome (14, (25) (26) (27) . Serum adiponectin levels are decreased in patients with type 2 diabetes mellitus and hypertension, in which serum leptin levels are increased. Serum adiponectin levels are also inversely correlated with insulin resistance in contrast to serum leptin levels. Recently, a negative correlation between serum adiponectin and leptin levels was reported, and leptin and adiponectin were suggested as determinants of each other (28 (16) (17) (18) 29) .
Discussion
In this study, we measured serum leptin levels concurrently with adiponectin levels in OSAS patients. Our results suggested that the increasing severity of OSAS induces an increase in the serum leptin concentration, however the serum adiponectin level does not simply depend on the severity of obesity or OSAS. The serum adiponectin level may be regulated by various mechanisms, including age and lipid disorders, and associated with increasing hypopnea-related oxyhemoglobin desaturation in OSAS patients. Serum leptin levels are strongly reflected in the degree of obesity, especially the percentage of body fat and BMI (6, 22). Obesity is known as the most common feature of type 2 diabetes, and high levels of serum leptin have often been shown in diabetic patients (23). Recent studies showed that leptin levels are strongly correlated with insulin resistance assessed by the serum insulin level and HOMA-IR, independent of body fat percentage and BMI
Obesity is also recognized as an essential feature of OSAS. Previous investigations have reported that serum leptin levels in OSAS patients were significantly higher than in control subjects and positively correlated with BMI (5, 24). Furthermore, there was a positive correlation between leptin and insulin resistance and the high incidence of atherosclerotic disease in patients with OSAS
T a b l e 4 .
On the other hand, several reports have suggested that age is one of the determinants of serum adiponectin (30, 31) , Shand et al (32) 
